The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | Reflecting on IBC 2025: highlights and areas for further research
Felipe Prósper, MD, PhD, University of Navarra, Pamplona, Spain, reflects on the 2025 Intercepting Blood Cancers (IBC) Workshop, sharing his highlights and identifying areas where further research is needed. He notes the value of connecting different diseases with similar behaviors, and emphasizes that a deeper understanding of the biology of disease transformation is needed before designing trials. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think this meeting is a great meeting. One of the things that I like the most is the fact that we establish connections between different diseases with similar behaviors. So we talked about smoldering myeloma, we talked about clonal hematopoiesis and myeloid malignancies and the same for lymphoid malignancies. And even though these are different diseases, they have a lot of commonalities and we address the questions a little differently in each one of those diseases and I think this is very useful because we learn from the others...
I think this meeting is a great meeting. One of the things that I like the most is the fact that we establish connections between different diseases with similar behaviors. So we talked about smoldering myeloma, we talked about clonal hematopoiesis and myeloid malignancies and the same for lymphoid malignancies. And even though these are different diseases, they have a lot of commonalities and we address the questions a little differently in each one of those diseases and I think this is very useful because we learn from the others. For instance in this meeting I actually look forward to the keynote speakers because they bring insights even from solid tumors from other perspectives that can actually feed us with new ideas on how to address some of the questions. We are talking quite a lot about treatment as well. I think it’s in some ways a little premature because we still don’t understand very well the biology of this transformation from precursor stages to malignant diseases and we need to know more about the biology. I actually would suggest that more biologic insights before the trials is something that we need to do.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
